334
Participants
Start Date
December 31, 2013
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
IMMU-107
Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
placebo
placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
Gemcitabine
Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
Medical University Vienna, Vienna
University Hospital Leuven, Leuven
New York Presbyterian Hospital/Weill Cornell Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
SUNY Upstate Medical University, Syracuse
Institut Paoli-Calmettes, Marseille
Institut Paoli-Calmettes, Marseille
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center/Hillman Cancer Center, Pittsburgh
University of Pennsylvania Abramson Cancer Center, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Maryland Medical Center, Baltimore
Virginia Oncology Associates, Norfolk
Hospital Universitario Gregorio Marañón, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario La Paz, Madrid
Centro Integral Oncologico Clara Campal, Madrid
Baptist Cancer Institute, Jacksonville
Cancer Specialists of North Florida, Jacksonville
Institut Bergonie, Bordeaux
Michael and Dianne Bienes Comprehensive Cancer Center - Holy Cross Hospital, Fort Lauderdale
CRLC Val D'Aurelle, Montpellier
Center for Biomedical Research, Knoxville
University of Tennessee Medical Center, Cancer Institute, Knoxville
University of Mississippi Medical Center, Jackson
Ashland-Bellefonte Cancer Center, Ashland
Hospital Sant Joan de Reu, Reus
The Ohio State University - Comprehensive Cancer Center, Columbus
ICO René Gauducheau, Nantes
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Indiana University Health Goshen Center for Cancer Care, Goshen
Barbara Ann Karmanos Cancer Institute, Detroit
Henry Ford Health System, Detroit
Hospital Miguel Servet, Zaragoza
Masonic Cancer Center, University of Minnesota, Minneapolis
Illinois Cancer Specialists, Arlington Heights
Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Centre Léon Bérard Cancerologie Medicale, Lyon
Stephenson Cancer Center, Oklahoma City
Hopital Cochin, Paris
Mary Crowley Medical Research Center, Dallas
Texas Oncology - Tyler, Tyler
Oncology Consultants, Houston
Texas Oncology - McAllen, McAllen
Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise
Soroka Medical Center, Beersheba
Banner MD Anderson, Gilbert
Comprehensive Cancer Centers of Nevada, Las Vegas
Cedars-Sinai Medical Center, Los Angeles
Pacific Shores Medical Group, Long Beach
City of Hope National Medical Center, Duarte
University of Washington, Seattle
Virginia Mason Medical Center, Seattle
Rambam Medical Center, Haifa
Whittingham Cancer Center, Norwalk
Dartmouth Hitchcock Medical Center, Lebanon
Stony Brook University Medical Center, Stony Brook
University of North Carolina Hospitals, Lineberger Comprehensive Cancer Center, Chapel Hill
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Hershey
Krankenhaus der Elisabethinen Linz, Linz
Cancer Care Manitoba, Winnepeg
Centre Hospitalier Université de Sherbrooke, Sherbrooke
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie - Warszawa, Warsaw
Hospital Vall D'Hebrón, Barcelona
Lead Sponsor
Gilead Sciences
INDUSTRY